Vacinação com BCG e redução do risco de asma

Souza‐Machado, Adelmir; Cruz, Álvaro Augusto

doi:10.1590/s1806-37132010000300001

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BCG presents recognized immunomodulatory properties [78] and is associated with reduced risk of asthma [79]. Immunization via BCG provides relief from airway inflammation through the inhibition of a TGF-β1mediated epithelial-to-mesenchymal transition (EMT), inhibiting the related remodeling of the respiratory tract accompanied with loss of lung epithelial integrity and fibrotic evolution [80].…”

Section: Bacillus Calmette-guérinmentioning

confidence: 99%

Drug repurposing against COVID-19: focus on anticancer agents

Ciliberto

Mancini

Paggi³

2020

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Background: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing. Main Body: Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of clinical use. This can allow their fast-track evaluation in phase II-III clinical trials, or even within straightforward compassionate use. Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virusinfected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their energy metabolism, in order to comply to the "viral program". Indeed, the same features are seen in cancer cells, making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral replication. Short Conclusion: To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate cancer drugs that can be repurposed for the treatment of COIVD-19.

show abstract

Section: Bacillus Calmette-guérinmentioning

confidence: 99%

Drug repurposing against COVID-19: focus on anticancer agents

Ciliberto

Mancini

Paggi³

2020

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

Bacillus Calmette-Guerin alleviates airway inflammation and remodeling by preventing TGF-β₁induced epithelial–mesenchymal transition

Tian

Huo

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Bacillus Calmette-Guerin (BCG) is a potent agent for the prevention of tuberculosis. Current studies have regarded BCG as an immunomodulator. However, there is little information on whether it can be used to inhibit airway inflammation and airway remodeling caused by asthma. Therefore, in this study, we investigate the role of epithelial-mesenchymal transition (EMT) in airway inflammation and airway remodeling as well as the possible therapeutic mechanism of BCG for the treatment of asthma. Wistar rats were sensitized and challenged by ovalbumin for 2 weeks or 8 weeks. BCG was subcutaneously administered daily before every ovalbumin challenge to determine its therapeutic effects. The 2 weeks model group showed extensive eosinophilia, chronic inflammatory responses, bronchial wall thickening, airway epithelium damage, increased levels of transforming growth factor β 1 (TGF-β) in both bronchoalveolar lavage fluid and sera, decreased expression of epithelial marker E-cadherin, and increased expressions of mesenchymal markers α-smooth muscle actin (α-SMA) and Fibronectin (Fn). Except for inflammatory responses, all responses were more significant in the 8 weeks model group which displayed characteristics of airway remodeling including subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia. When compared with the model groups, BCG administration inhibited airway inflammation and airway remodeling, decreased TGF-β levels, upregulated expression of E-cadherin, and downregulated expression of α-SMA and Fn. The present study suggests for the first time that increased secretion of TGF- β induced by asthmatic chronic inflammation may result in EMT, which is one of the most important mechanisms of airway inflammation and airway remodeling seen with asthma. BCG alleviates airway inflammation and airway remodeling by preventing TGF-β induced EMT, therefore BCG may be a new therapy for treating asthma.

show abstract

Vacinação com BCG e redução do risco de asma

Cited by 2 publications

References 19 publications

Drug repurposing against COVID-19: focus on anticancer agents

Drug repurposing against COVID-19: focus on anticancer agents

Bacillus Calmette-Guerin alleviates airway inflammation and remodeling by preventing TGF-β₁induced epithelial–mesenchymal transition

Contact Info

Product

Resources

About

Vacinação com BCG e redução do risco de asma

Cited by 2 publications

References 19 publications

Drug repurposing against COVID-19: focus on anticancer agents

Drug repurposing against COVID-19: focus on anticancer agents

Bacillus Calmette-Guerin alleviates airway inflammation and remodeling by preventing TGF-β1induced epithelial–mesenchymal transition

Contact Info

Product

Resources

About

Bacillus Calmette-Guerin alleviates airway inflammation and remodeling by preventing TGF-β₁induced epithelial–mesenchymal transition